Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 9/20 | 0.51 |
| ▸ | CA2 | P00918 | 9/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389760 | 0.93 | MAOA (0.64) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL5564023 | 0.93 | MAOA (0.59) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL5124510 | 0.91 | TDP1 (0.67) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL3341020 | 0.85 | TDP1 (0.67) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL15049400 | 0.84 | MAOA (0.57) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL23394950 | 0.84 | TDP1 (0.56) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL1788759 | 0.83 | MAOA (0.53) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL11175075 | 0.81 | TDP1 (0.50) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL11168529 | 0.81 | TDP1 (0.53) | MAOAMAOBTDP1CA1CA2 | |
| SCHEMBL5093291 | 0.81 | MAOA (0.54) | MAOAMAOBTDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118451087-A | Disulfide oligosaccharide compounds and complexes | 生物技术公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118369122-A | Oligosaccharide complex and use thereof | 生物技术公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7314884-B2 | non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile | HOFFMANN-LA ROCHE INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | disclosed |
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1480976-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-6723716-B1 | BACTERICIDE FOR STAPHYLOCOCCUS | ESSENTIAL THERAPEUTICS, INC. | 2004-04-20 | — | — | US | disclosed |
| US-6686381-B2 | COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003072577-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-1222194-A1 | 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF | Essential Therapeutics, Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001021623-A1 | 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225141-A1 | THIAZOLE DERIVATIVES | SLC5A1, GPR119, TAS1R1 | MAOA 3021/4885MAOB 2876/4885TDP1 3074/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | MAOA 2399/4885MAOB 2125/4885TDP1 1233/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | MAOA 3098/4885MAOB 3102/4885TDP1 565/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | MAOA 2399/4885MAOB 2125/4885TDP1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.